Vasostatin,a Calreticulin Fragment,Inhibits Angiogenesis and Suppresses Tumor Growth |
| |
Authors: | Sandra E. Pike Lei Yao Karen D. Jones Barry Cherney Ettore Appella Kazuyasu Sakaguchi Hira Nakhasi Julie Teruya-Feldstein Peter Wirth Ghanshyam Gupta Giovanna Tosato |
| |
Affiliation: | From the *Center for Biologics Evaluation and Research, Rockville, Maryland 20852; and the ‡Laboratory of Cell Biology, the §Laboratory of Pathology, and the ‖Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 |
| |
Abstract: | An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus–immortalized cell line and identified as fragments of calreticulin. The purified recombinant NH2-terminal domain of calreticulin (amino acids 1–180) inhibited the proliferation of endothelial cells, but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin significantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Compared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets proliferating endothelial cells, vasostatin has a unique potential for cancer treatment. |
| |
Keywords: | endothelial cells angiogenesis cell growth cancer antitumor agent |
|
|